Cargando…

Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases

Treatment of early relapses of T lymphoblastic leukemia/lymphoma is often unsuccessful. We tested an experimental regimen containing daratumumab and nelarabine in two young patients with early relapses of T lymphoblastic lymphoma and T-ALL, respectively. Both patients achieved a deep complete remiss...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molle, Ingolf, Petruskevicius, Irma, Kamper, Peter, d'Amore, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763564/ https://www.ncbi.nlm.nih.gov/pubmed/35047223 http://dx.doi.org/10.1155/2022/9722787

Ejemplares similares

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022)

Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
por: Cooper, Todd M
Publicado: (2007)

Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia
por: Reilly, Kelly M, et al.
Publicado: (2009)

Nelarabine-induced rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia: a case report
por: Utsumi, Akari, et al.
Publicado: (2022)

MRI findings of nelarabine‐related rhabdomyolysis in a patient with refractory T‐cell acute lymphoblastic leukemia
por: Mukai, Daiki, et al.
Publicado: (2023)

Rhabdomyolysis induced by nelarabine
por: Späth, Christian, et al.
Publicado: (2022)

Nelarabine Associated Myotoxicity and Rhabdomyolysis
por: Haider, Mahnur, et al.
Publicado: (2015)

Clinical Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
por: Tisi, Maria Chiara, et al.
Publicado: (2015)

Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
por: Cerrano, Marco, et al.
Publicado: (2022)

SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine
por: Rothenburger, Tamara, et al.
Publicado: (2020)

Nelarabine in the Treatment of Refractory T-Cell Malignancies
por: Roecker, Andrew M., et al.
Publicado: (2010)

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway
por: Lonetti, Annalisa, et al.
Publicado: (2016)

Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant
por: McEwan, Ashley, et al.
Publicado: (2020)

Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia
por: Martino, R, et al.
Publicado: (1998)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

T-Cell Lymphoblastic Leukemia/Lymphoma: Relapse 16 Years after First Remission
por: Elreda, Lauren, et al.
Publicado: (2014)

Classical Hodgkin Lymphoma Presenting with Severe, Recurrent Hypothermic Episodes
por: Hansen, Jonas Juul, et al.
Publicado: (2018)

P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Testicular relapse of acute lymphoblastic leukemia()
por: Carolan, Alexandra, et al.
Publicado: (2023)

Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
por: Stanulla, Martin, et al.
Publicado: (2023)

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
por: Topp, Max S., et al.
Publicado: (2021)

Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab
por: Marco-Ayala, Javier, et al.
Publicado: (2020)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
por: Kaimila, Bongani, et al.
Publicado: (2017)

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
por: Baumann, Niklas, et al.
Publicado: (2022)

Daratumumab–bortezomib–dexamethasone use in relapsed POEMS syndrome
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

Histologically transformed follicular lymphoma exhibits protein profiles different from both non-transformed follicular and de novo diffuse large B-cell lymphoma
por: Ludvigsen, M, et al.
Publicado: (2015)

Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma
por: Cao, Wenyue, et al.
Publicado: (2022)

Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling
por: Honoré, Bent, et al.
Publicado: (2022)

Pericardial Relapse of Acute Lymphoblastic Leukemia (ALL)
por: Maslov, Diana V., et al.
Publicado: (2021)

A Unique Case of Relapsed B-Acute Lymphoblastic Leukemia/Lymphoma as an Isolated Omental Mass
por: Kantekure, Kanchan, et al.
Publicado: (2014)

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
por: Garrett, May, et al.
Publicado: (2019)

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
por: Thudium Mueller, Karen, et al.
Publicado: (2021)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma
por: Bapatla, Anusha, et al.
Publicado: (2021)

Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study
por: Sun, Weili, et al.
Publicado: (2018)

FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia
por: Yu, Sung-Liang, et al.
Publicado: (2020)

Acute lymphoblastic leukemia relapse presenting with optic nerve infiltration
por: Dini, Gianluca, et al.
Publicado: (2023)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
por: Gibson, Amber, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6h6fnlf34tnjeeuoll1pssdc6b